An experimental technique removes T cells that aid in vitro tumor growth.
© GEORGE RETSECK
Tumors (purple cells) recruit abnormally high numbers of potently immune-suppressing Tregs, which repress effector T cells (1) and prevent cancer destruction. Addition of anti-TNFR2 monoclonal antibodies (2) targets and kills TNFR2-expressing Tregs, thereby boosting the activity of effector T cells, which attack the tumor (3). The antibodies can also directly kill tumor cells that express the TNFR2 receptor.
Read the full story.
Lab safety rules dictate that one must tie back long hair. Rosemarie Hansen learned the hard way when an open flame turned her locks into a lesson.
View this Issue
Learn how improving sampling, standardization, and calibration streamlines quality control processes.
In this webinar, Benoit Derrien will discuss new strategies using enzymatically synthesized DNA for gene construction.
Choosing between plate reader-based assays and mass spectrometry solutions is a key decision for scientists when evaluating technology options for their laboratories.
- Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network - Hypothermic preservation technology eliminates costs and inefficiencies of cold-chain logistics to enhance biomedical research and cell therapy development
Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Singleron Biotechnologies and Hamilton Bonaduz AG today announced the official launch of Tensor under their strategic partnership.
Zymo Research is proud to introduce the RNome Disruptive Research Grant, that is designed to empower scientists mapping the RNome and advance our overallunderstanding of RNA.
